Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged.
Latest Features
LATEST ARTICLES
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.
Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers ready that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
The Downstream Effect of Misrepresented Clinical Trial Data
Data quality issues borne out in clinical trials don’t always reach peer reviewers, and as a result, may not reach prescribers, either.
NSAIDs in Head and Neck Cancer Bring New Meaning to Precision Medicine
Patients with PIK3CA-altered head and neck cancers lived longer if they took NSAIDs, suggesting old drugs may have new clinical uses.
Active Surveillance: Is it an Appropriate Approach for Thyroid Cancer?
In patients with thyroid cancer, active surveillance has been controversial because surgery is the standard of care.
Chemobrain: Experts Weigh in on Very Real — and Growing — Problem
Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott.
Tumor-Infiltrating Lymphocytes and Prognosis in Early-Stage TNBC
Higher numbers of TILs seen in early-stage triple-negative breast cancer has been associated with better clinical outcomes.
Myeloma Trial Aims to Use Genetic Profile for Treatment Optimization
To improve options for patients with refractory disease, researchers seek to bolster data behind genetic profiling as a way to guide the selection of treatment.
Dysfunctional CD8+ T Cells Remain Active in Melanoma Tumor Microenvironment
Many CD8+ T cells in the melanoma microenvironment are becoming progressively dysfunctional yet remain highly proliferative, according to researchers.
Treatment of Early FL More Effective With PET-Staging and Contemporary RT
Treatment of stage I/II follicular lymphoma (as determined by FDG-PET parameters) resulted in better freedom from progression and OS rates compared with historical numbers.
Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
Although patients with CML may not be eligible for TKI discontinuation based on transcript alone, the type of transcript seen may have some implications for loss of treatment remission.
Overall Survival in Patients With Stage IV ALK-Positive Non-Small Cell Lung Cancer Treated With Crizotinib
Researchers found that survival was associated with the number of metastatic sites, but not affected by brain metastasis.
Want to read more?
Please login or register first to view this content.
